Nektar Therapeutics Inc. is getting $50 million up front and retaining co-promotion rights in a deal with Bayer HealthCare AG covering its Phase II inhaled amikacin product for pneumonia. (BioWorld Today)

Sucampo Pharmaceuticals Inc. priced its initial public offering of 3.8 million shares at $11.50 each for gross proceeds of $43.1 million, half of what the company had hoped for when it first filed to go public more than a year ago. (BioWorld Today)